Zaire Ebola virus

Summary

Alias: Zaire ebolavirus, ZEBOV

Top Publications

  1. ncbi Physicochemical properties of Marburg virus: evidence for three distinct virus strains and their relationship to Ebola virus
    M P Kiley
    Division of Viral Diseases, Centers for Disease Control, Atlanta, Georgia 30333
    J Gen Virol 69:1957-67. 1988
  2. ncbi Classification, structure, and replication of filoviruses
    H Feldmann
    Institut fur Virologie, Philipps Universitat, Marburg, Germany
    Curr Top Microbiol Immunol 235:1-21. 1999
  3. pmc Ebola virus can be effectively neutralized by antibody produced in natural human infection
    T Maruyama
    Departments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 73:6024-30. 1999
  4. ncbi Epitopes involved in antibody-mediated protection from Ebola virus
    J A Wilson
    Virology Division, U S Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702 5011, USA
    Science 287:1664-6. 2000
  5. ncbi Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury
    Z Y Yang
    Vaccine Research Center, National Institutes of Health, 40 Convent Drive, Bethesda, Maryland 20892 3005, USA
    Nat Med 6:886-9. 2000
  6. pmc Crystal structure of the matrix protein VP40 from Ebola virus
    A Dessen
    European Molecular Biology Laboratory Grenoble Outstation, 6 rue Jules Horowitz, 38000 Grenoble, France
    EMBO J 19:4228-36. 2000
  7. pmc The Ebola virus VP35 protein functions as a type I IFN antagonist
    C F Basler
    Department of Microbiology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Proc Natl Acad Sci U S A 97:12289-94. 2000
  8. ncbi Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry
    A Takada
    Laboratory of Microbiology, Graduate School of Veterinary Medicine, Sapporo, 060 0818, Japan
    Virology 278:20-6. 2000
  9. pmc Ebola virus VP40-induced particle formation and association with the lipid bilayer
    L D Jasenosky
    Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin Madison, Madison, Wisconsin 53706, USA
    J Virol 75:5205-14. 2001
  10. ncbi Biosynthesis and role of filoviral glycoproteins
    H Feldmann
    Canadian Science Centre for Human and Animal Health, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2
    J Gen Virol 82:2839-48. 2001

Research Grants

  1. RNA Interference for the Treatment of Ebola and Marburg Hemorrhagic Fever
    Ian MacLachlan; Fiscal Year: 2013
  2. MEGAN LOUISE SHAW; Fiscal Year: 2014
  3. Analysis of the Ebola Virus VP24 Channel Protein
    RONALD HARTY; Fiscal Year: 2003
  4. EBOLA VIRUS INTERFERON-ANTAGONISTS AND VIRULENCE
    CHRISTOPHER BASLER; Fiscal Year: 2003
  5. Lassa and Nipah Virus Interferon-Antagonists
    CHRISTOPHER BASLER; Fiscal Year: 2003
  6. Ebola Virus VP40-Host Interactions In VIvo
    RONALD HARTY; Fiscal Year: 2005
  7. Budding of Negative-sense RNA Viruses
    RONALD HARTY; Fiscal Year: 2006
  8. Packaging of Ebola Virus RNA into Budding VLPs
    RONALD HARTY; Fiscal Year: 2008
  9. Prime/Boost Immunization against HIV-1 by Viral Vectors
    Matthias Schnell; Fiscal Year: 2003
  10. Killed Rhabdoviruses as Novel Anthrax Vaccines
    Matthias Schnell; Fiscal Year: 2006

Patents

  1. METHODS AND DEVICES FOR REAL-TIME DIAGNOSTIC TESTING (RDT) FOR EBOLA AND OTHER INFECTIOUS DISEASES
  2. Primer set, Assay kit and Detecting method for Zaire Ebolavirus
  3. Primer set, Assay kit and Detecting method for Zaire Ebolavirus
  4. METHODS OF DETECTING EBOLA
  5. Chimeric filovirus glycoprotein
  6. Recombinant biologically contained filovirus
  7. Screen for inhibitors of filovirus and uses therefor
  8. HUMAN EBOLA VIRUS SPECIES AND COMPOSITIONS AND METHODS THEREOF
  9. No title supplied
  10. Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein

Scientific Experts

Detail Information

Publications169 found, 100 shown here

  1. ncbi Physicochemical properties of Marburg virus: evidence for three distinct virus strains and their relationship to Ebola virus
    M P Kiley
    Division of Viral Diseases, Centers for Disease Control, Atlanta, Georgia 30333
    J Gen Virol 69:1957-67. 1988
    ..In addition, these studies confirm the belief that MBG and EBO viruses are members of the new virus family, the Filoviridae...
  2. ncbi Classification, structure, and replication of filoviruses
    H Feldmann
    Institut fur Virologie, Philipps Universitat, Marburg, Germany
    Curr Top Microbiol Immunol 235:1-21. 1999
  3. pmc Ebola virus can be effectively neutralized by antibody produced in natural human infection
    T Maruyama
    Departments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 73:6024-30. 1999
    ..The neutralizing antibody may be useful in vaccine design and as a prophylactic agent against Ebola virus infection...
  4. ncbi Epitopes involved in antibody-mediated protection from Ebola virus
    J A Wilson
    Virology Division, U S Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702 5011, USA
    Science 287:1664-6. 2000
    ..The identification of protective mAbs has important implications for developing vaccines and therapies for Ebola virus...
  5. ncbi Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury
    Z Y Yang
    Vaccine Research Center, National Institutes of Health, 40 Convent Drive, Bethesda, Maryland 20892 3005, USA
    Nat Med 6:886-9. 2000
    ..These findings indicate that GP, through its mucin domain, is the viral determinant of Ebola pathogenicity and likely contributes to hemorrhage during infection...
  6. pmc Crystal structure of the matrix protein VP40 from Ebola virus
    A Dessen
    European Molecular Biology Laboratory Grenoble Outstation, 6 rue Jules Horowitz, 38000 Grenoble, France
    EMBO J 19:4228-36. 2000
    ..The crystal structure reveals how the molecule may be able to switch from a monomeric conformation to a hexameric form, as observed in vitro. Its implications for the assembly process are discussed...
  7. pmc The Ebola virus VP35 protein functions as a type I IFN antagonist
    C F Basler
    Department of Microbiology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Proc Natl Acad Sci U S A 97:12289-94. 2000
    ..The Ebola virus VP35 therefore is likely to inhibit induction of type I IFN in Ebola virus-infected cells and may be an important determinant of Ebola virus virulence in vivo...
  8. ncbi Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry
    A Takada
    Laboratory of Microbiology, Graduate School of Veterinary Medicine, Sapporo, 060 0818, Japan
    Virology 278:20-6. 2000
    ..We suggest that integrins, especially the beta1 group, might interact with the GP and perhaps be involved in Ebola virus entry into cells...
  9. pmc Ebola virus VP40-induced particle formation and association with the lipid bilayer
    L D Jasenosky
    Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin Madison, Madison, Wisconsin 53706, USA
    J Virol 75:5205-14. 2001
    ..These data suggest that VP40 binds the lipid bilayer in an efficient yet structurally complex fashion...
  10. ncbi Biosynthesis and role of filoviral glycoproteins
    H Feldmann
    Canadian Science Centre for Human and Animal Health, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2
    J Gen Virol 82:2839-48. 2001
  11. pmc Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture
    Gabriele Neumann
    Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin Madison, Madison, Wisconsin 53706, USA
    J Virol 76:406-10. 2002
    ....
  12. pmc Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses
    Sina Bavari
    Dept of Cell Biology and Biochemistry, U S Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702 5011, USA
    J Exp Med 195:593-602. 2002
    ....
  13. pmc Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP
    Takeshi Noda
    Laboratory of Microbiology, Department of Disease Control, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo 060 0818, Japan
    J Virol 76:4855-65. 2002
    ..These results demonstrated the central role of VP40 in formation of the filamentous structure of Ebola virions and may suggest an interaction between VP40 and GP in morphogenesis...
  14. ncbi The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein
    Yue Huang
    Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Mol Cell 10:307-16. 2002
    ..This distinct mechanism of regulation for filovirus assembly suggests new approaches for viral therapies and vaccines for Ebola and related viruses...
  15. pmc Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding
    Ziying Han
    Laboratory 412 Laboratory 413, Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6049, USA
    J Virol 77:1793-800. 2003
    ..These data indicate that VP24 possesses structural features commonly associated with viral matrix proteins and that VP24 may have a role in virus assembly and budding...
  16. pmc Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4
    Jillian M Licata
    Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6049, USA
    J Virol 77:1812-9. 2003
    ..These results provide important insights into the complex interplay between viral and host proteins during the late stages of Ebola virus budding...
  17. ncbi Ebola virus matrix protein VP40 interaction with human cellular factors Tsg101 and Nedd4
    Joanna Timmins
    European Molecular Biology Laboratory, 6 rue Jules Horowitz, 38042 Grenoble, France
    J Mol Biol 326:493-502. 2003
    ..These results suggest that hNedd4 and Tsg101 may play complimentary roles at a late stage of the assembly process, by recruiting cellular factors of two independent pathways to the site of budding at the plasma membrane...
  18. pmc The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3
    Christopher F Basler
    Department of Microbiology, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
    J Virol 77:7945-56. 2003
    ..These data suggest that in Ebola virus-infected cells, VP35 inhibits the induction of antiviral genes, including the IFN-beta gene, by blocking IRF-3 activation...
  19. pmc Ebola virus-like particles protect from lethal Ebola virus infection
    Kelly L Warfield
    US Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA
    Proc Natl Acad Sci U S A 100:15889-94. 2003
    ..Together, our data suggest that eVLPs represent a promising vaccine candidate for protection against Ebola virus infections and a much needed tool to examine the genesis and nature of immune responses to Ebola virus...
  20. pmc In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding
    Rekha G Panchal
    Developmental Therapeutics Program, Target Structure Based Drug Discovery Group, Science Applications International Corporation, National Cancer Institute, Frederick, MD 21702 1201, USA
    Proc Natl Acad Sci U S A 100:15936-41. 2003
    ..We also report the successful application of the biarsenic fluorophore, FlAsH, combined with a tetracysteine tag for imaging of Ebola VP40 in live cells...
  21. pmc Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles
    Jillian M Licata
    Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, 3800 Spruce St, Philadelphia, PA 19104 6049, USA
    J Virol 78:7344-51. 2004
    ..the C-terminal 50 amino acids of NP may be important for interacting with and enhancing release of VP40 VLPs. These findings provide a more complete understanding of the role of VP40 and additional Ebola virus proteins during budding...
  22. pmc Association of ebola virus matrix protein VP40 with microtubules
    Gordon Ruthel
    USAMRIID, 1425 Porter St, Frederick, MD 21702, USA
    J Virol 79:4709-19. 2005
    ..These results suggest that microtubules may play an important role in the Ebola virus life cycle and potentially provide a novel target for therapeutic intervention against this highly pathogenic virus...
  23. ncbi Analysis of Ebola virus and VLP release using an immunocapture assay
    George Kallstrom
    Division of Virology, U S Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA
    J Virol Methods 127:1-9. 2005
    ..Furthermore, this assay can be used in surrogate models in non-biocontainment environment, facilitating both basic research on the mechanism of EBOV assembly and budding as well as drug-discovery research...
  24. pmc Ebola virus VP40 late domains are not essential for viral replication in cell culture
    Gabriele Neumann
    Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin Madison, 2015 Linden Dr, Madison, WI 53706, USA
    J Virol 79:10300-7. 2005
    ..These findings indicate that the Ebola VP40 late domain motifs enhance virus replication but are not absolutely required for virus replication in cell culture...
  25. pmc Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function
    Victoria M Wahl-Jensen
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba
    J Virol 79:10442-50. 2005
    ..Furthermore, sGP, the major soluble glycoprotein of Ebola virus, seems to possess an anti-inflammatory role by protecting the endothelial cell barrier function...
  26. pmc VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice
    Sven Enterlein
    Department of Virology, Philipps University Marburg, Hans Meerwein str 3, 35043 Marburg, Germany
    Antimicrob Agents Chemother 50:984-93. 2006
    ..Together, these data suggest that antisense PMO and P-PMO have the potential to control EBOV infection and are promising therapeutic candidates...
  27. pmc Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence
    John C Kash
    Department of Microbiology, School of Medicine, University of Washington, Box 358070, Seattle, Washington 98195 8070, USA
    J Virol 80:3009-20. 2006
    ..expression by characterizing the regulation of gene expression responses in human liver cells infected with Zaire Ebolavirus (ZEBOV), Reston Ebolavirus (REBOV), and Marburgvirus (MARV), using transcriptional profiling and ..
  28. pmc Functional mapping of the nucleoprotein of Ebola virus
    Shinji Watanabe
    Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin Madison, 2015 Linden Dr, Madison, Wisconsin 53706, USA
    J Virol 80:3743-51. 2006
    ..These data advance our understanding of the functional region(s) of Ebola virus NP, which in turn should improve our knowledge of the Ebola virus life cycle and its extreme pathogenicity...
  29. pmc Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation
    St Patrick Reid
    Department of Microbiology, Box 1124, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
    J Virol 80:5156-67. 2006
    ..These data suggest that VP24 is likely to be an important virulence determinant that allows EBOV to evade the antiviral effects of IFNs...
  30. pmc Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling
    Washington B Cardenas
    Department of Microbiology, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
    J Virol 80:5168-78. 2006
    ..These data support the hypothesis that dsRNA binding may contribute to VP35 IFN antagonist function. However, additional mechanisms of inhibition, at a point proximal to the IRF-3 kinases, most likely also exist...
  31. pmc Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication
    Amy L Hartman
    Special Pathogens Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, MS G 14, Atlanta, GA 30329, USA
    J Virol 80:6430-40. 2006
    The VP35 protein of Zaire Ebola virus is an essential component of the viral RNA polymerase complex and also functions to antagonize the cellular type I interferon (IFN) response by blocking activation of the transcription factor IRF-3...
  32. pmc Molecular determinants of Ebola virus virulence in mice
    Hideki Ebihara
    Institute of Medical Science, University of Tokyo, Tokyo, Japan
    PLoS Pathog 2:e73. 2006
    b>Zaire ebolavirus (ZEBOV) causes severe hemorrhagic fever in humans and nonhuman primates, with fatality rates in humans of up to 90%. The molecular basis for the extreme virulence of ZEBOV remains elusive...
  33. pmc Mapping of the VP40-binding regions of the nucleoprotein of Ebola virus
    Takeshi Noda
    Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin Madison, 2015 Linden Drive, Madison, WI 53706, USA
    J Virol 81:3554-62. 2007
    ..These findings enhance our understanding of Ebola virus assembly and in so doing move us closer to the identification of targets for the development of antiviral compounds to combat Ebola virus infection...
  34. pmc Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1
    St Patrick Reid
    Department of Microbiology, Box 1124, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
    J Virol 81:13469-77. 2007
    The Zaire ebolavirus protein VP24 was previously demonstrated to inhibit alpha/beta interferon (IFN-alpha/beta)- and IFN-gamma-induced nuclear accumulation of tyrosine-phosphorylated STAT1 (PY-STAT1) and to inhibit IFN-alpha/beta- and IFN-..
  35. pmc Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling
    Mathieu Mateo
    Laboratoire des Filovirus, INSERM U758, University Claude Bernard Lyon 1, 21 Av Tony Garnier, 69365 Lyon Cedex 07, France
    J Virol 84:1169-75. 2010
    ..We demonstrate that loss of function correlates with loss of binding to KPNalpha proteins. Thus, the VP24 IFN antagonist function requires the ability of VP24 to interact with KPNalpha...
  36. pmc Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35
    Daisy W Leung
    Department of Biochemistry, Biophysics and Molecular Biology, Iowa State University, Ames, Iowa, USA
    Nat Struct Mol Biol 17:165-72. 2010
    ..These results suggest that simultaneous recognition of dsRNA backbone and blunt ends provides a mechanism by which Ebola VP35 antagonizes host dsRNA sensors and immune responses...
  37. pmc Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells
    Lawrence W Leung
    Department of Microbiology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Immunol Cell Biol 89:792-802. 2011
    ..However, cells that utilize the TLR pathway can circumvent this inhibition, suggesting that the presence of multiple viral sensors enables the host to overcome viral immune evasion mechanisms...
  38. pmc A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding
    R N Harty
    Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, 3800 Spruce Street, Philadelphia, PA 19104 6049, USA
    Proc Natl Acad Sci U S A 97:13871-6. 2000
    ..Last, these studies imply that VP40 likely plays an important role in filovirus budding, and that budding of retroviruses, rhabdoviruses, and filoviruses may proceed via analogous mechanisms...
  39. pmc Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway
    Nancy J Sullivan
    Vaccine Research Center, National Institute for Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20814, USA
    J Virol 79:547-53. 2005
    ..By altering the trafficking of select cellular proteins, Ebola virus GP inflicts cell damage and may facilitate immune escape by the virus...
  40. ncbi Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level
    Nathalie Alazard-Dany
    Filovirus Laboratory, Claude Bernard University Lyon 1, INSERM U758, IFR 128 Biosciences Lyon Gerland, France
    J Gen Virol 87:1247-57. 2006
    ..These findings indicate that the synthesis of EBOV GP in virus-infected cells is controlled well by several mechanisms that do not allow GP overexpression and hence the early appearance of its cytotoxic properties...
  41. ncbi Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent
    Kelly L Warfield
    US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
    J Infect Dis 196:S276-83. 2007
    ..In this report, we describe a novel inactivation technique for Zaire Ebola virus (ZEBOV) that uses the photoinduced alkylating probe 1,5-iodonaphthylazide (INA)...
  42. ncbi Lymphocyte death in a mouse model of Ebola virus infection
    Steven B Bradfute
    Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
    J Infect Dis 196:S296-304. 2007
    A striking feature of Zaire Ebola virus (ZEBOV) infection in nonhuman primates is the rapid depletion of T and NK lymphocytes by apoptosis...
  43. pmc Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus
    Mohammad F Saeed
    Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America
    PLoS Pathog 4:e1000141. 2008
    ..A novel and critical role of the PI3K signaling pathway was demonstrated in cell entry of Zaire Ebola virus (ZEBOV)...
  44. pmc Structural and functional characterization of Reston Ebola virus VP35 interferon inhibitory domain
    Daisy W Leung
    Department of Biochemistry, Biophysics, and Molecular Biology, Iowa State University, Ames, IA 50011, USA
    J Mol Biol 399:347-57. 2010
    ..Previous studies also suggest that REBOV is less effective at inhibiting host innate immune responses than Zaire Ebola virus (ZEBOV) or Marburg virus...
  45. pmc Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS ONE 4:e5547. 2009
    b>Zaire ebolavirus (ZEBOV) produces a lethal viral hemorrhagic fever in humans and non-human primates.
  46. doi Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, MA 02118, USA
    Lancet 375:1896-905. 2010
    We previously showed that small interfering RNAs (siRNAs) targeting the Zaire Ebola virus (ZEBOV) RNA polymerase L protein formulated in stable nucleic acid-lipid particles (SNALPs) completely protected guineapigs when administered ..
  47. doi Genetic factors of Ebola virus virulence in guinea pigs
    Ekaterina Subbotina
    Department of Molecular Virology, State Research Center of Virology and Biotechnology Vector, Koltsovo, 630559, Russia
    Virus Res 153:121-33. 2010
    b>Zaire ebolavirus (ZEBOV) causes severe hemorrhagic fever in primates, whereas in guinea pigs it induces a nonlethal infection with a mild fever and subsequent recovery...
  48. ncbi Molecular characterization of an isolate from the 1989/90 epizootic of Ebola virus Reston among macaques imported into the United States
    Allison Groseth
    Special Pathogens Program, Canadian Science Centre for Human and Animal Health, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2
    Virus Res 87:155-63. 2002
    ..The sequence determination provides the basis for the development of a reverse genetics system for Ebola virus Reston, which is needed to study differences in pathogenicity among filoviruses...
  49. ncbi Filovirus-like particles as vaccines and discovery tools
    Kelly L Warfield
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702 5011, USA
    Expert Rev Vaccines 4:429-40. 2005
    ..Thus, in addition to their use as a vaccine, VLPs are currently being used as tools to learn lessons about filovirus pathogenesis, immunology, replication and assembly requirements...
  50. pmc Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus
    Danher Wang
    Division of Biodefense Vaccines, GenPhar, Inc, 871 Lowcountry Blvd, Mount Pleasant, South Carolina 29464, USA
    J Virol 80:2738-46. 2006
    ..Two species of EBOV, Sudan ebolavirus (SEBOV) and Zaire ebolavirus (ZEBOV), have been responsible for all of the deadly human outbreaks resulting from this virus...
  51. pmc Ebola virus VP35-VP40 interaction is sufficient for packaging 3E-5E minigenome RNA into virus-like particles
    Reed F Johnson
    Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, 3800 Spruce St, Philadelphia, PA 19104, USA
    J Virol 80:5135-44. 2006
    ..Results from immunoprecipitation-reverse transcriptase PCR experiments suggest that VP35 confers specificity of the nucleocapsid for viral genomic RNA by direct VP35-RNA interactions...
  52. pmc Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology
    Reed F Johnson
    Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, 3800 Spruce St, Philadelphia, PA 19104, USA
    Virol J 3:31. 2006
    ..Overall, these findings indicate that major changes in morphology of VP40 VLPs were likely not responsible for enhanced budding of VP40 VLPs in the presence of GP, NP and/or VP35...
  53. pmc Interaction of Tsg101 with Marburg virus VP40 depends on the PPPY motif, but not the PT/SAP motif as in the case of Ebola virus, and Tsg101 plays a critical role in the budding of Marburg virus-like particles induced by VP40, NP, and GP
    Shuzo Urata
    First Department of Forensic Science, National Research Institute of Police Science, Kashiwa 277 0882, Japan
    J Virol 81:4895-9. 2007
    ..These findings provide new insights into the mechanism of MARV budding...
  54. pmc Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts, USA
    PLoS Pathog 4:e1000225. 2008
    ..In order to address this concern, we evaluated the safety of the recombinant VSV vector expressing the Zaire ebolavirus glycoprotein (VSVDeltaG/ZEBOVGP) in six rhesus macaques infected with simian-human immunodeficiency virus (..
  55. pmc Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs
    Kathleen C Prins
    Department of Microbiology, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Virol 84:3004-15. 2010
    ..Moreover, these studies provide a framework for the development of antivirals targeting this critical EBOV virulence factor...
  56. pmc T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus
    Andrew S Kondratowicz
    Department of Microbiology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA
    Proc Natl Acad Sci U S A 108:8426-31. 2011
    ..Here, we show that T-cell Ig and mucin domain 1 (TIM-1) binds to the receptor binding domain of the Zaire Ebola virus (EBOV) glycoprotein, and ectopic TIM-1 expression in poorly permissive cells enhances EBOV infection by 10- ..
  57. doi The 2014 Ebola virus disease outbreak in West Africa
    Derek Gatherer
    Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YQ, UK
    J Gen Virol 95:1619-24. 2014
    ..The causative agent has now been identified as an outlier strain of Zaire Ebola virus. The full geographical extent and degree of severity of the outbreak, its zoonotic origins and its possible ..
  58. pmc The Ebola virus matrix protein VP40 selectively induces vesiculation from phosphatidylserine-enriched membranes
    Smita P Soni
    From the Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, South Bend, Indiana 46617 and
    J Biol Chem 289:33590-7. 2014
    ..Taken together, these studies suggest that PM phosphatidylserine may be an important component of Ebola virus budding and that VP40 may be able to mediate PM scission...
  59. pmc Next-generation sequencing reveals a controlled immune response to Zaire Ebola virus challenge in cynomolgus macaques immunized with vesicular stomatitis virus expressing Zaire Ebola virus glycoprotein (VSVΔG/EBOVgp)
    Fredrik Barrenas
    Department of Microbiology, University of Washington, Seattle, Washington, USA Washington National Primate Research Center, University of Washington, Seattle, Washington, USA Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden
    Clin Vaccine Immunol 22:354-6. 2015
    Vesicular stomatitis virus expressing Zaire Ebola virus (EBOV) glycoprotein (VSVΔG/EBOVgp) could be used as a vaccine to meet the 2014 Ebola virus outbreak...
  60. pmc In silico prediction of Ebola Zaire GP(1,2) immuno-dominant epitopes for the Balb/c mouse
    Debargh K Dutta
    Division of Biology, Chemistry and Materials Science, Center for Devices and Radiological Health, FDA, Silver Spring, MD, 20993, USA
    BMC Immunol 16:59. 2015
    ..Zaire, a recombinant FV human Fc fusion protein, has been shown to confer protection against mouse adapted Zaire Ebola virus. The present studies are focused upon identifying immunodominant epitopes using in silico methods and ..
  61. doi The healthcare workers' clinical skill set requirements for a uniformed international response to the Ebola virus disease outbreak in West Africa: the Canadian perspective
    Dennis Marion
    Royal Canadian Medical Services, Canadian Armed Forces, Ottawa, Ontario, Canada Department of Medicine and Division of Infectious Disease, University of Alberta, Edmonton, Alberta, Canada
    J R Army Med Corps 162:207-11. 2016
    Since December 2013, the Zaire Ebola virus disease (EVD) epidemic has ravaged West Africa...
  62. pmc Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona
    Andrea Marzi
    Laboratory of Virology
    J Infect Dis 214:S360-S366. 2016
    ..One of these vaccines is vesicular stomatitis virus (VSV)-EBOV, also known as rVSV-ZEBOV, a fast-acting vaccine against EBOV and so far the only vaccine with reported efficacy against EBOV infections in ..
  63. doi Identification of novel VP35 inhibitors: Virtual screening driven new scaffolds
    Ji Xia Ren
    College of Life Science, Liaocheng University, Liaocheng 252059, People s Republic of China Institute of Medicinal Plant Development, Chinese Academy of Medical Science and Peking Union Medical College, 151 Malianwa North Road, Haidian District, Beijing 100193, People s Republic of China
    Biomed Pharmacother 84:199-207. 2016
    ..The mapping results of hit compounds onto pharmacophore model and 3D QSAR model, and the molecular interactions of the potential inhibitors with the active site residues have been discussed in detail...
  64. pmc Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus
    Chad E Mire
    Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, United States of America Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America
    PLoS Negl Trop Dis 7:e2600. 2013
    ..in place of the VSV glycoprotein, have shown 100% efficacy against homologous Sudan ebolavirus (SEBOV) or Zaire ebolavirus (ZEBOV) challenge in NHPs...
  65. doi Multiple phosphorylable sites in the Zaire Ebolavirus nucleoprotein evidenced by high resolution tandem mass spectrometry
    Jérémy Peyrol
    Commissariat a l Energie Atomique, iBEB SBTN LDCAE, Bagnols sur Ceze, France
    J Virol Methods 187:159-65. 2013
    The 739-amino-acid nucleoprotein (NP) of Zaire Ebolavirus (ZEBOV) plays a key role in Ebola virion formation and replication. A stable HEK-293 cell line capable of producing an N-ter 6His-tagged recombinant form of NP - ZEBOV was created...
  66. pmc Cathepsin B & L are not required for ebola virus replication
    Andrea Marzi
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America
    PLoS Negl Trop Dis 6:e1923. 2012
    ..The most pathogenic and best-studied species is Zaire ebolavirus (ZEBOV)...
  67. pmc A mutation in the Ebola virus envelope glycoprotein restricts viral entry in a host species- and cell-type-specific manner
    Osvaldo Martinez
    Icahn School of Medicine at Mount Sinai, New York, NY, USA
    J Virol 87:3324-34. 2013
    b>Zaire Ebola virus (EBOV) is a zoonotic pathogen that causes severe hemorrhagic fever in humans. A single viral glycoprotein (GP) mediates viral attachment and entry...
  68. ncbi Generation and epitope mapping of a monoclonal antibody against nucleoprotein of Ebola virus
    Xiaodu Wang
    Forestry and Biotechnology School, Zhejiang Agriculture and Forestry University, Lin an 311300, Zhejiang, China
    Sheng Wu Gong Cheng Xue Bao 28:1317-27. 2012
    ..The MAb generated via immunization of mice with prokaryotically expressed recombinant NP of the Zaire Ebola virus (ZEBOV-NP) was specific to ZEBOV-NP and able to recognize ZEBOV-NP expressed in prokaryotic and eukaryotic ..
  69. pmc Immunopathogenesis of severe acute respiratory disease in Zaire ebolavirus-infected pigs
    Charles K Nfon
    National Center for Foreign Animal Disease, Canadian Food Inspection Agency, Winnipeg, Manitoba, Canada
    PLoS ONE 8:e61904. 2013
    Ebola viruses (EBOV) are filamentous single-stranded RNA viruses of the family Filoviridae. Zaire ebolavirus (ZEBOV) causes severe haemorrhagic fever in humans, great apes and non-human primates (NHPs) with high fatality rates...
  70. doi Review of Ebola virus infections in domestic animals
    H M Weingartl
    National Centre for Foreign Animal Disease NCFAD, Canadian Food Inspection Agency CFIA, Canadian Science Centre for Human and Animal Health, Winnipeg, Canada
    Dev Biol (Basel) 135:211-8. 2013
    ..Evaluation of current human vaccine candidates or development of veterinary vaccines de novo for EBOV might need to be considered, especially if pigs or dogs are implicated in the transmission of an African species of EBOV to humans...
  71. pmc Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates
    Gary Wong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Sci Transl Med 4:158ra146. 2012
    ..experimental vaccines have been successful in protecting rodents and nonhuman primates (NHPs) from the lethal Zaire ebolavirus (ZEBOV) infection...
  72. pmc Antigen capture enzyme-linked immunosorbent assay for specific detection of Reston Ebola virus nucleoprotein
    Tetsuro Ikegami
    Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, Musashimurayama, Tokyo 208 0011, Japan
    Clin Diagn Lab Immunol 10:552-7. 2003
    ..capture ELISA using a monoclonal antibody (MAb), 3-3D, which reacted not only to the nucleoprotein (NP) of Zaire Ebola virus (EBO-Z) but also to the NPs of Sudan (EBO-S) and Reston Ebola (EBO-R) viruses...
  73. pmc Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses
    Michael Garbutt
    Special Pathogens Program, National Microbiology Laboratory, Health Canada, Winnipeg, Manitoba, Canada R3E 3R2
    J Virol 78:5458-65. 2004
    ..None of the rVSVs displayed pathogenic potential in animals. The rVSV expressing the Zaire Ebola virus transmembrane glycoprotein mediated protection in mice against a lethal Zaire Ebola virus challenge...
  74. pmc Wave-like spread of Ebola Zaire
    Peter D Walsh
    Max Planck Institute for Evolutionary Primatology, Leipzig, Germany
    PLoS Biol 3:e371. 2005
    In the past decade the Zaire strain of Ebola virus (ZEBOV) has emerged repeatedly into human populations in central Africa and caused massive die-offs of gorillas and chimpanzees...
  75. ncbi Chimpanzee adenovirus vaccine protects against Zaire Ebola virus
    Gary P Kobinger
    Special Pathogens Program, National Microbiology Laboratory, Health Canada, Canadian Science Centre for Human and Animal Health, University of Manitoba, Winnipeg, Canada
    Virology 346:394-401. 2006
    This study evaluated the use of a chimpanzee-based adenovirus vaccine in mouse and Guinea pigs models of Zaire Ebola virus (ZEBOV) infection...
  76. ncbi Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference
    Thomas W Geisbert
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702 5011, USA
    J Infect Dis 193:1650-7. 2006
    ..Here, we describe the development of a potential therapy for EBOV infection that is based on small interfering RNAs (siRNAs)...
  77. pmc Infection of naive target cells with virus-like particles: implications for the function of ebola virus VP24
    Thomas Hoenen
    Institut fur Virologie, Philipps Universitat Marburg, Marburg, Germany
    J Virol 80:7260-4. 2006
    ..have recently been established for several negative-strand RNA viruses, including the highly pathogenic Zaire ebolavirus (ZEBOV), and allow study of the viral life cycle under biosafety level 2 conditions...
  78. ncbi Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses
    Kavitha Yaddanapudi
    Jerome L and Dawn Greene Infectious Disease Laboratory, Mailman School of Public Health, Columbia University, 722 West 168th St, New York, NY 10032, USA
    FASEB J 20:2519-30. 2006
    ..Whereas Marburg (MARV), Ebola Zaire (ZEBOV), and Ebola Sudan (SEBOV) viruses are pathogenic in humans, apes, and monkeys, Ebola Reston (REBOV) is pathogenic ..
  79. ncbi Ebola outbreak killed 5000 gorillas
    Magdalena Bermejo
    Ecosystèmes Forestiers d Afrique Centrale ECOFAC, Box Postale 15115 Libreville, Gabon
    Science 314:1564. 2006
    Over the past decade, the Zaire strain of Ebola virus (ZEBOV) has repeatedly emerged in Gabon and Congo...
  80. ncbi Rapid and simple detection of Ebola virus by reverse transcription-loop-mediated isothermal amplification
    Yohei Kurosaki
    National Research Institute of Police Science, Kashiwa 277 0882, Japan
    J Virol Methods 141:78-83. 2007
    ..reverse transcription-loop mediated isothermal amplification (RT-LAMP) assay for the rapid detection of Zaire ebolavirus (ZEBOV), the most virulent species of EBOV, targeting the trailer region of the viral genome...
  81. ncbi Spatial and temporal patterns of Zaire ebolavirus antibody prevalence in the possible reservoir bat species
    X Pourrut
    Institut de Recherche pour le Developpement, UR178, Franceville, Gabon
    J Infect Dis 196:S176-83. 2007
    To characterize the distribution of Zaire ebolavirus (ZEBOV) infection within the 3 bat species (Epomops franqueti, Hypsignathus monstrosus, and Myonycteris torquata) that are possible reservoirs, we collected 1390 bats during 2003-2006 ..
  82. ncbi High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings
    Jonathan S Towner
    Special Pathogens Branch, National Center for Zoonotic, Vector Borne, and Enteric Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Infect Dis 196:S205-12. 2007
    ..Using Zaire Ebola virus as an example, we describe here the development of a high-throughput protocol for RNA extraction and ..
  83. ncbi In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein
    Hideki Ebihara
    Department of Special Pathogens, International Research Center for Infectious Diseases, University of Tokyo, Tokyo, Japan
    J Infect Dis 196:S313-22. 2007
    To facilitate an understanding of the molecular aspects of the pathogenesis of Zaire ebolavirus (ZEBOV) infection, we generated 2 different recombinant viruses expressing enhanced green fluorescent protein (eGFP) from additional ..
  84. ncbi Cytokine and chemokine expression in humans infected with Sudan Ebola virus
    Karen L Hutchinson
    Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Infect Dis 196:S357-63. 2007
    ..factor- alpha and interferon (IFN)- gamma , which had been found to be increased in patients with fatal Zaire Ebola virus infection, were not increased in any of the patients with SEBOV infection...
  85. ncbi In vitro evaluation of antisense RNA efficacy against filovirus infection, by use of reverse genetics
    Allison Groseth
    National Laboratory for Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada
    J Infect Dis 196:S382-9. 2007
    ..Therefore, we explored the application of minigenomes as screening tools to identify functional siRNA targets under biosafety level 2 conditions...
  86. ncbi Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever
    Steven M Jones
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Canada
    J Infect Dis 196:S404-12. 2007
    ..In the present study, we used the mouse model for Ebola hemorrhagic fever to assess the safety and efficacy of a vaccine based on a live attenuated vesicular stomatitis virus expressing the Zaire ebolavirus (ZEBOV) glycoprotein.
  87. pmc The marburg virus 3' noncoding region structurally and functionally differs from that of ebola virus
    Sven Enterlein
    Institute of Virology, Philipps University Marburg, Marburg, Germany
    J Virol 83:4508-19. 2009
    We have previously shown that the first transcription start signal (TSS) of Zaire Ebola virus (ZEBOV) is involved in formation of an RNA secondary structure regulating VP30-dependent transcription activation...
  88. pmc Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus
    Thomas W Geisbert
    Department of Microbiology, National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Virol 83:7296-304. 2009
    ..having one single-injection vaccine capable of protecting nonhuman primates against Sudan ebolavirus (SEBOV), Zaire ebolavirus (ZEBOV), Cote d'Ivoire ebolavirus (CIEBOV), and Marburgvirus (MARV)...
  89. pmc Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine
    Jason S Richardson
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS ONE 4:e5308. 2009
    ..this report, we modified the common recombinant adenovirus serotype 5-based Ebola vaccine expressing the wild-type ZEBOV glycoprotein sequence from a CMV promoter (Ad-CMVZGP)...
  90. pmc Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition
    Osvaldo Martinez
    Department of Microbiology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cell Microbiol 12:148-57. 2010
    ..Thus, cathepsin L plays a minimal, if any, role in EBOV infection in human DCs. The inflammatory cytokine TNFalpha modulates cathepsin B activity and affects EBOV entry into and infection of human DCs...
  91. pmc High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon
    Pierre Becquart
    Unité des Maladies Virales Emergentes, Centre International de Recherches Medicales de Franceville, Franceville, Gabon
    PLoS ONE 5:e9126. 2010
    To better understand Zaire ebolavirus (ZEBOV) circulation and transmission to humans, we conducted a large serological survey of rural populations in Gabon, a country characterized by both epidemic and non epidemic regions...
  92. pmc Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species
    Lisa E Hensley
    Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA
    PLoS Pathog 6:e1000904. 2010
    ..can be generated against this novel species, cynomolgus macaques were immunized with DNA/rAd5 vaccines expressing ZEBOV and SEBOV glycoprotein (GP) prior to lethal challenge with BEBOV...
  93. doi Advanced antisense therapies for postexposure protection against lethal filovirus infections
    Travis K Warren
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA
    Nat Med 16:991-4. 2010
    ..dosing strategies initiated 30-60 min after infection, protects>60% of rhesus monkeys against lethal Zaire Ebola virus (ZEBOV) and 100% of cynomolgus monkeys against Lake Victoria Marburg virus (MARV) infection...
  94. pmc Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes
    Mohammad F Saeed
    Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, United States of America
    PLoS Pathog 6:e1001110. 2010
    b>Zaire ebolavirus (ZEBOV), a highly pathogenic zoonotic virus, poses serious public health, ecological and potential bioterrorism threats. Currently no specific therapy or vaccine is available...
  95. pmc The Tyro3 receptor kinase Axl enhances macropinocytosis of Zaire ebolavirus
    Catherine L Hunt
    Dept Microbiology, University of Iowa, Iowa City, IA 52242, USA
    J Virol 85:334-47. 2011
    Axl, a plasma membrane-associated Tyro3/Axl/Mer (TAM) family member, is necessary for optimal Zaire ebolavirus (ZEBOV) glycoprotein (GP)-dependent entry into some permissive cells but not others...
  96. pmc Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice
    Krishnamurthy Konduru
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Vaccine 29:2968-77. 2011
    ..We expressed the extracellular domain of the Zaire Ebola virus (ZEBOV) GP fused to the Fc fragment of human IgG1 (ZEBOVGP-Fc) in mammalian cells and showed that GP ..
  97. doi Involvement of viral envelope GP2 in Ebola virus entry into cells expressing the macrophage galactose-type C-type lectin
    Katsuaki Usami
    Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo 113 0033, Japan
    Biochem Biophys Res Commun 407:74-8. 2011
    ..Differences in the mortality among different species of the Ebola viruses, i.e., Zaire ebolavirus (ZEBOV) and Reston ebolavirus (REBOV), correspond to the in vitro infectivity of the pseudo-typed virus ..
  98. pmc Tyrosine kinase receptor Axl enhances entry of Zaire ebolavirus without direct interactions with the viral glycoprotein
    Melinda A Brindley
    Department of Microbiology, University of Iowa, Iowa City, IA 52242, USA
    Virology 415:83-94. 2011
    In a bioinformatics-based screen for cellular genes that enhance Zaire ebolavirus (ZEBOV) transduction, AXL mRNA expression strongly correlated with ZEBOV infection...
  99. doi Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus
    Stephan Olschlager
    Department of Virology, Bernhard Nocht Institute for Tropical Medicine, Bernhard Nocht Str 74, 20359 Hamburg, Germany
    Antiviral Res 91:89-93. 2011
    ..Analogous experiments performed with Zaire Ebola virus showed that IMPDH inhibitors are also active against this virus, although to a lesser extent than against ..
  100. doi Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology
    Douglas S Reed
    U S Army Medical Research Institute of Infectious Diseases, Frederick, MD, USA
    Microbes Infect 13:930-6. 2011
    There is little known concerning the disease caused by Zaire ebolavirus (ZEBOV) when inhaled, the likely route of exposure in a biological attack...
  101. pmc Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses
    Joseph E Blaney
    Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 85:10605-16. 2011
    ..ii) replication-deficient, and (iii) chemically inactivated rabies virus (RABV) vaccines expressing Zaire Ebola virus (ZEBOV) glycoprotein (GP) by a reverse genetics system based on the SAD B19 RABV wildlife vaccine...

Research Grants13

  1. RNA Interference for the Treatment of Ebola and Marburg Hemorrhagic Fever
    Ian MacLachlan; Fiscal Year: 2013
    ..in humans and nonhuman primates with case fatality rates as high as 90% for some species or strains such as Zaire ebolavirus (ZEBOV)...
  2. MEGAN LOUISE SHAW; Fiscal Year: 2014
    ..The assay is based on the Zaire Ebola virus minigenome assay, which because it is plasmid-based and does not involve infectious virus, can be performed ..
  3. Analysis of the Ebola Virus VP24 Channel Protein
    RONALD HARTY; Fiscal Year: 2003
    ..Overall this application will address key mechanisms of Ebola virus pathogenesis that may lead to the development of novel paradigms with direct impact on the development of therapeutic approaches. ..
  4. EBOLA VIRUS INTERFERON-ANTAGONISTS AND VIRULENCE
    CHRISTOPHER BASLER; Fiscal Year: 2003
    ..VP35 and VP24 may also prove to be attractive targets for new antiviral agents. Inhibition of anti-IFN factors may sensitize Ebola virus infected cells to the antiviral effects of IFN and may also enhance the effect of antiviral agents. ..
  5. Lassa and Nipah Virus Interferon-Antagonists
    CHRISTOPHER BASLER; Fiscal Year: 2003
    ..abstract_text> ..
  6. Ebola Virus VP40-Host Interactions In VIvo
    RONALD HARTY; Fiscal Year: 2005
    ..These studies will be fundamental for our understanding of Ebola virus budding and necessary for the successful development of future therapeutic approaches. ..
  7. Budding of Negative-sense RNA Viruses
    RONALD HARTY; Fiscal Year: 2006
    ....
  8. Packaging of Ebola Virus RNA into Budding VLPs
    RONALD HARTY; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  9. Prime/Boost Immunization against HIV-1 by Viral Vectors
    Matthias Schnell; Fiscal Year: 2003
    ....
  10. Killed Rhabdoviruses as Novel Anthrax Vaccines
    Matthias Schnell; Fiscal Year: 2006
    ..Lastly, Anthrax challenge experiments of the most promising constructs in mice will indicate if the inducted responses are protective against Anthrax infection. ..
  11. A novel rhabdovirus-based anthrax vaccine
    Matthias Schnell; Fiscal Year: 2007
    ..The general concept, if proven successful, may also lead to a general technique for developing more effective vaccines for other important pathogens. [unreadable] [unreadable] [unreadable]..
  12. Astrocytes and Restricted HIV-1 Replication
    Matthias Schnell; Fiscal Year: 2007
    ..Thus, these complementary approaches will be utilized to analyze, on molecular levels, the mechanisms of HIV-1 reservoirs and persistence in human astrocytes. [unreadable] [unreadable]..
  13. RABIES VIRUS-BASED VECTORS AS AN HIV-1 VACCINE
    Matthias Schnell; Fiscal Year: 2008
    ..Thus, we will pursue several complementary approaches designed to further improve our HIV-1 vaccines, study their anti-HIV directed immunogenicity in detail, and test their efficacy in the rhesus macaque model system. ..

Patents10

  1. METHODS AND DEVICES FOR REAL-TIME DIAGNOSTIC TESTING (RDT) FOR EBOLA AND OTHER INFECTIOUS DISEASES
    Patent Number: WO2016057749-A; Date:2016-04-14
  2. Primer set, Assay kit and Detecting method for Zaire Ebolavirus
    Patent Number: JP2016116503-A; Date:2016-06-30
  3. Primer set, Assay kit and Detecting method for Zaire Ebolavirus
    Patent Number: WO2016098892-A; Date:2016-06-23
  4. METHODS OF DETECTING EBOLA
    Patent Number: WO2016069853-A2; Date:2016-05-06
  5. Chimeric filovirus glycoprotein
    Patent Number: WO02079239-A2; Date:2002-10-10
  6. Recombinant biologically contained filovirus
    Patent Number: WO2009128867-A2; Date:2009-10-22
  7. Screen for inhibitors of filovirus and uses therefor
    Patent Number: WO2010053573-A1; Date:2010-05-14
  8. HUMAN EBOLA VIRUS SPECIES AND COMPOSITIONS AND METHODS THEREOF
    Patent Number: EP2350270-A2; Date:2011-08-03
  9. No title supplied
    Patent Number: WO2006037038-A1; Date:2006-04-06
  10. Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein
    Patent Number: WO0116183-A1; Date:2001-03-08